Effect of the Postbiotics on Complications Treatment in Elderly Hemodialysis Patients

Launched by PEKING UNIVERSITY FIRST HOSPITAL · May 8, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how a special treatment called postbiotics can help improve the quality of life and nutritional status of older patients who are on hemodialysis for kidney failure. Hemodialysis is a treatment that filters waste and excess fluids from the blood when the kidneys are not working properly. The study will involve participants aged 65 and older who have been receiving hemodialysis for at least six months.

During the trial, participants will be divided into two groups: one group will receive the postbiotics for 12 weeks, while the other group will get a placebo, which looks like the treatment but has no active ingredients. After the first 12 weeks, the groups will switch, and the placebo group will receive the postbiotics for the next 12 weeks. Throughout the study, researchers will measure changes in the participants' quality of life and nutritional health to see if the postbiotics make a difference. If you or a loved one meet the age and treatment criteria, you may be eligible to participate in this important study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• Investigators must maintain a screening log of all potential study candidates that includes limited information about the potential candidate, date, and outcome of the screening process (e.g. enrolled into study, reason for ineligibility, or refused to participate). After signing an informed consent form, potential patients must meet all of the criteria:
• • 1. Age ≥65 years.
• • 2. Receiving maintenance hemodialysis therapy for at least 6 months.
• Exclusion Criteria:
• The following exclusion criteria must NOT be present for each subject:
• • 1. Subjects with medical history that might affect oral feeding (e.g. intestinal obstruction, gastrointestinal bleeding, acute pancreatitis and accidental inhalation) within the last 1 month prior to screening.
• • 2. Subjects with medical history that might affect gastrointestinal functions (e.g. inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), short bowel syndrome (SBS), et al.).
• • 3. Subjects who cannot communicate and collaborate normally.